SCHEMBL10293204

SCHEMBL10293204

CC(C)NC(=O)c1cc2cc(S(=O)(=O)N3CCCCCC3)ccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.52
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
ATM Q13315 2/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TP53 P04637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PABPC1 P11940 1/20 0.47
APOBEC3A P31941 1/20 0.47
EIF4H Q15056 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
ALOX15 P16050 1/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 3/20 0.46
GLA P06280 1/20 0.46
MCOLN3 Q8TDD5 2/20 0.46
HCRTR1 O43613 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293113 0.89 KMT2A (0.58) ALDH1A1MAPTGAAKDM4EKMT2A
SCHEMBL10293210 0.88 NAMPT (0.54) NAMPTALDH1A1MAPTATMGAA
SCHEMBL10293122 0.85 NAMPT (0.59) NAMPTALDH1A1MAPTATMGAA
SCHEMBL8276726 0.85 KDM4E (0.50) NAMPTALDH1A1MAPTATMGAA
SCHEMBL8278394 0.85 CNR1 (0.47) ALDH1A1MAPTGAAKDM4ETP53
SCHEMBL10293112 0.82 ALDH1A1 (0.61) ALDH1A1GAAKDM4EKMT2ASMN1; SMN2
SCHEMBL10293176 0.82 ALDH1A1 (0.61) ALDH1A1GAAKDM4EKMT2ASMN1; SMN2
SCHEMBL10293280 0.81 HRH4 (0.63) MAPTATMGAAKDM4EKMT2A
SCHEMBL10293117 0.81 HRH4 (0.63) MAPTATMGAAKDM4EKMT2A
SCHEMBL10293168 0.81 HRH4 (0.63) MAPTATMGAAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C NAMPT 2751/4885ALDH1A1 3826/4885MAPT 1243/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C NAMPT 2751/4885ALDH1A1 3826/4885MAPT 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.